Inhibitors in hemophilia A: Advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 8, 2009, Pages 735-751

  Ananyeva, Natalya M ^a   Lee, Timothy K ^a   Jain, Nisha ^b   Shima, Midori ^c   Saenko, Evgueni L ^d  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

Author keywords

Bypass therapy; Epitope; Factor VIII; Hemophilia A; Inhibitor

Indexed keywords

A2 ANTIBODY; A3 ANTIBODY; ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; C1 ANTIBODY; C2 ANTIBODY; CATALYTIC ANTIBODY; LIPOSOME; MONOCLONAL ANTIBODY; NN 1731; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY TITER; BLEEDING; BLOOD CLOTTING FACTOR 8 ANTIBODY PRODUCTION; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENE MUTATION; GENETIC RISK; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOPATHOLOGY; IMMUNOPRECIPITATION; METHODOLOGY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE DRUG DOSE; SPOT BLOTCH; THROMBIN TIME; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY; THROMBOEMBOLISM;

ANIMALS; ANTIBODIES, CATALYTIC; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 77449091890     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1245106     Document Type: Review

References (122)

1. Fay P J. Factor VIII structure and function. Int J Hematol 2006 83 (2) 103-108
2. Mannucci P M. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008 14 (suppl 3) 10-18
3. DiMichele D M. Inhibitors in hemophilia: a primer. In: Treatment of hemophilia. 4th ed Montreal, Quebec, Canada World Federation of Hemophilia 2008
4. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006 12 (suppl 6) 15-22
5. Astermark J, Berntorp E, White G C., Kroner B L., MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001 7 (3) 267-272
6. Scharrer I, Bray G L., Neutzling O. Incidence of inhibitors in haemophilia A patientsa review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999 5 (3) 145-154
7. Viel K R., Ameri A, Abshire T C. et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009 360 (16) 1618-1627
8. Oldenburg J, Tuddenham E. Inhibitors to factor VIIImolecular basis In: Lee CA, Berntorp EE, Hoots WK Textbook of hemophilia. New York, NY Blackwell 2005 59-63
9. Kempton C L., White G C. II. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009 113 (1) 11-17
10. Goudemand J, Rothschild C, Demiguel V et al, FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006 107 (1) 46-51
11. Gouw S C., van den Berg H M., le Cessie S, van der Bom J G. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007 5 (7) 1383-1390
12. Gouw S C., van der Bom J G., Auerswald G, Ettinghausen C E., Tedgrd U, van den Berg H M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007 109 (11) 4693-4697
13. Hoots W K., Lusher J. High-titer inhibitor development in hemophilia A: lack of product specificity. J Thromb Haemost 2004 2 (2) 358-359
14. Saenko E L., Ananyeva N M., Tuddenham E G., Kemball-Cook G. Factor VIIInovel insights into form and function. Br J Haematol 2002 119 (2) 323-331
15. Scandella D H., Nakai H, Felch M et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res 2001 101 (5) 377-385
16. Healey J F., Lubin I M., Nakai H et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995 270 (24) 14505-14509
17. Fay P J., Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999 274 (42) 29826-29830
18. Fay P J., Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998 273 (30) 19049-19054
19. Ansong C, Miles S M., Fay P J. Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12. J Thromb Haemost 2006 4 (4) 842-847
20. Healey J F., Parker E T., Barrow R T., Langley T J., Church W R., Lollar P. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost 2007 5 (3) 512-519
21. Healey J F., Barrow R T., Tamim H M. et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998 92 (10) 3701-3709
22. Scandella D, Gilbert G E., Shima M et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995 86 (5) 1811-1819
23. Pratt K P., Shen B W., Takeshima K, Davie E W., Fujikawa K, Stoddard B L. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999 402 (6760) 439-442
24. Stoilova-McPhie S, Villoutreix B O., Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002 99 (4) 1215-1223
25. Spiegel P C. Jr, Jacquemin M, Saint-Remy J M., Stoddard B L., Pratt K P. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001 98 (1) 13-19
26. Nogami K, Shima M, Giddings J C., Takeyama M, Tanaka I, Yoshioka A. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain. Int J Hematol 2007 85 (4) 317-322
27. Saenko E L., Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 1997 272 (29) 18007-18014
28. Gilbert G E., Kaufman R J., Arena A A., Miao H, Pipe S W. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002 277 (8) 6374-6381
29. Saenko E L., Shima M, Gilbert G E., Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996 271 (44) 27424-27431
30. Meeks S L., Healey J F., Parker E T., Barrow R T., Lollar P. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007 110 (13) 4234-4242
31. Nogami K, Shima M, Hosokawa K et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999 274 (43) 31000-31007
32. Nogami K, Shima M, Hosokawa K et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000 275 (33) 25774-25780 (Pubitemid 30687082)
33. Meeks S L., Healey J F., Parker E T., Barrow R T., Lollar P. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 2008 112 (4) 1151-1153
34. Lenting P J., van de Loo J W., Donath M J., van Mourik J A., Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996 271 (4) 1935-1940
35. Fijnvandraat K, Celie P H., Turenhout E A. et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998 91 (7) 2347-2352
36. Zhong D, Saenko E L., Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998 92 (1) 136-142
37. Foster P A., Fulcher C A., Houghten R A., de Graaf Mahoney S, Zimmerman T S. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1988 82 (1) 123-128
38. Lapan K A., Fay P J. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997 272 (4) 2082-2088
39. Raut S, Villard S, Grailly S et al. Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor. Thromb Haemost 2003 90 (3) 385-397
40. Barrow R T., Healey J F., Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000 95 (2) 564-568
41. Jacquemin M, Benhida A, Peerlinck K et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000 95 (1) 156-163
42. Takeshima K, Smith C, Tait J, Fujikawa K. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003 89 (5) 788-794
43. Hsu T C., Pratt K P., Thompson A R. The factor VIII C1 domain contributes to platelet binding. Blood 2008 111 (1) 200-208
44. Lacroix-Desmazes S, Bayry J, Misra N et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002 346 (9) 662-667
45. Lacroix-Desmazes S, Wootla B, Dasgupta S et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol 2006 177 (2) 1355-1363
46. Wootla B, Mahendra A, Dimitrov J D. et al. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Lett 2009 583 (15) 2565-2572
47. Gilles J G., Jacquemin M G., Saint-Remy J M. Factor VIII inhibitors. Thromb Haemost 1997 78 (1) 641-646
48. Lavigne-Lissalde G, Lacroix-Desmazes S, Wootla B et al. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice. Thromb Haemost 2007 98 (1) 138-147
49. Fulcher C A., de Graaf Mahoney S, Roberts J R., Kasper C K., Zimmerman T S. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A 1985 82 (22) 7728-7732
50. Scandella D, De Graaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher C A. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci U S A 1988 85 (16) 6152-6156
51. Scandella D, Mattingly M, de Graaf S, Fulcher C A. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989 74 (5) 1618-1626
52. Koshihara K, Qian J, Lollar P, Hoyer L W. Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII. Blood 1995 86 (6) 2183-2190
53. Healey J F., Parker E T., Barrow R T., Langley T J., Church W R., Lollar P. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost 2009 102 (1) 35-41
54. Frank R. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supportsprinciples and applications. J Immunol Methods 2002 267 (1) 13-26
55. Albert T, Lange S, Oldenburg J et al. Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries [in German]. Hamostaseologie 2003 23 (1) 13-17
56. Albert T, Egler C, Jakuschev S et al. The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis. Thromb Haemost 2008 99 (3) 634-637
57. Kopecky E M., Greinstetter S, Pabinger I, Buchacher A, Römisch J, Jungbauer A. Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. J Immunol Methods 2006 308 (12) 90-100
58. Smith G P., Petrenko V A. Phage display. Chem Rev 1997 97 (2) 391-410
59. Villard S, Piquer D, Raut S, Lonetti J P., Saint-Remy J M., Granier C. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002 277 (30) 27232-27239
60. Villard S, Lacroix-Desmazes S, Kieber-Emmons T et al. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood 2003 102 (3) 949-952
61. Kessel C, Königs C, Linde R et al. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Mol Immunol 2008 46 (1) 8-15
62. Kessel C, Kreuz W, Klich K et al. Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies. ChemMedChem 2009 4 (8) 1364-1370
63. Martin P G., Sukhu K, Chambers E, Giangrande P L. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999 21 (2) 125-128
64. Shetty S, Ghosh K, Mohanty D. An ELISA assay for the detection of factor VIII antibodiescomparison with the conventional Bethesda assay in a large cohort of haemophilia samples. Acta Haematol 2003 109 (1) 18-22
65. Fulton R J., McDade R L., Smith P L., Kienker L J., Kettman J R. Jr. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 1997 43 (9) 1749-1756
66. Lavigne-Lissalde G, Tarrade C, Lapalud P et al. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 2008 99 (6) 1090-1096
67. FEIBA VH. Anti-inhibitor coagulant complex [package insert]. Westlake Village, CA Baxter Healthcare Corp 2005
68. Turecek P L., Vradi K, Gritsch H, Schwarz H P. FEIBA: mode of action. Haemophilia 2004 10 (Suppl 2) 3-9
69. Negrier C, Dargaud Y, Bordet J C. Basic aspects of bypassing agents. Haemophilia 2006 12 (suppl 6) 48-52 discussion 52-53
70. Vradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003 1 (11) 2374-2380
71. Hoffman M, Monroe D M. III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001 38 (4, Suppl 12) 6-9
72. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol 2006 43 (Suppl 1) S105-S107
73. Roberts H R., Monroe D M., White G C. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004 104 (13) 3858-3864
74. Lindley C M., Sawyer W T., Macik B G. et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994 55 (6) 638-648
75. Fridberg M J., Hedner U, Roberts H R., Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005 16 (4) 259-266
76. Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004 10 (4) 352-359
77. Shapiro A D., Gilchrist G S., Hoots W K., Cooper H A., Gastineau D A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998 80 (5) 773-778
78. Key N S., Aledort L M., Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998 80 (6) 912-918
79. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003 9 (4) 464-520 (Pubitemid 36874393)
80. Santagostino E, Mancuso M E., Rocino A, Mancuso G, Scaraggi F, Mannucci P M. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006 4 (2) 367-371
81. Dimichele D, Ngrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006 12 (4) 352-362
82. Astermark J, Donfield S M., DiMichele D M. et al, FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007 109 (2) 546-551
83. Knight C, Dan A M., Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther 2009 26 (1) 68-88
84. Donfield S M., Astermark J, Lail A E., Gilbert S A., Berntorp E, Fenoc Study Group. Value added: increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008 14 (2) 276-280
85. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009 15 (1) 3-10
86. Monroe D M., Hoffman M, Roberts H R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002 22 (9) 1381-1389
87. Srensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004 2 (1) 102-110
88. Shetty S, Vora S, Kulkarni B et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007 138 (4) 541-544
89. Allen G A., Hoffman M, Roberts H R., Monroe D M. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006 134 (3) 314-319
90. NovoSeven Coagulation Factor VIIa. (recombinant) [package insert]. Princeton, NJ Novo Nordisk A/S 2006
91. Hedner U. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Dis Mon 2003 49 (1) 39-48
92. Allen G A., Persson E, Campbell R A., Ezban M, Hedner U, Wolberg A S. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007 27 (3) 683-689
93. Srensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007 137 (2) 158-165
94. Holmberg H L., Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009 7 (9) 1517-1522
95. Mss J, Scharling B, Ezban M, Miller Srensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 2009 7 (2) 299-305
96. Stennicke H R., Ostergaard H, Bayer R J. et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008 100 (5) 920-928
97. Palm L, Jepsen T, Garmer S F. et al. Analysis and characterization of glycopegylated recombinant human FVIIA. J Thromb Haemost 2009 7 (suppl 2) Abstract PP-WE-585
98. Sorensen B, Karpf D, Groth A V. et al. Effect of glycopegylation on the pharmacokinetic properties of FVIIa. J Thromb Haemost 2007 5 (suppl 2) P-T-012
99. Yatuv R, Dayan I, Carmel-Goren L et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008 14 (3) 476-483
100. Weimer T, Wormsbcher W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008 99 (4) 659-667
101. Kronthaler U, Schmidbauer S, Liebing U et al. Prolonged half-life of recombinant factor VIIA fusion proteinsingle dose study in rabbits. J Thromb Haemost 2009 7 (Suppl 2) Abstract PP-TH-561
102. Pan J, Kim J, Zhu D et al. Binding to activated platelets and enhanced clotting properties of the recombinant FVIIa analogue Bay7. J Thromb Haemost 2009 7 (suppl 2) Abstract OC-WE-059
103. Liu T, Zhang X, Pan J et al. Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY866150) for acute and prophylactic treatments in hemophilia A (HemA) mice. J Thromb Haemost 2009 7 (Suppl 2) Abstract OC-WE-057
104. Doering C B., Healey J F., Parker E T., Barrow R T., Lollar P. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002 277 (41) 38345-38349 (Pubitemid 35154689)
105. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007 13 (3) 256-263
106. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003 1 (3) 450-455
107. Parameswaran R, Shapiro A D., Gill J C., Kessler C M., HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005 11 (2) 100-106
108. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams Z S., Kenet G, NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006 95 (4) 600-605
109. Lee D, Yoon B S., Spotts G, Ewenstein B M. Assessment of thrombotic adverse events (TAES) with activated prothrombin complex concentrates (APCCS): 17 year experience. J Thromb Haemost 2007 5 (Suppl 2) P-T-157
110. Allen G A., Hoffman M, Roberts H R., Monroe D M. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006 134 (3) 314-319
111. Schneiderman J, Rubin E, Nugent D J., Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007 13 (3) 244-248
112. Ng H J., Loh S M., Tan D C., Lee L H. Thrombosis associated with the use of recombinant activated factor VII: profiling two events. Thromb Haemost 2004 92 (6) 1448-1449
113. Srensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003 1 (3) 551-558
114. Srensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirementsan update on monitoring haemostatic response using thrombelastography. Haemophilia 2005 11 (Suppl 1) 1-6
115. Ingerslev J, Poulsen L H., Srensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003 9 (4) 348-352
116. Hayashi T, Tanaka I, Shima M et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004 10 (4) 397-400
117. Young G, Blain R, Nakagawa P, Nugent D J. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006 12 (6) 598-604
118. Hemker H C., Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003 33 (1) 4-15
119. Dargaud Y, Bguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005 93 (3) 475-480
120. Vradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003 1 (11) 2374-2380
121. Dargaud Y, Lienhart A, Negrier C. Monitoring of recombinant FVIIa by thrombin generation test. J Thromb Haemost 2007 5 (Suppl 2) P-M-176
122. Dargaud Y, Lienhart A, Meunier S et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005 11 (5) 552-558